Seeking Alpha

Salix, Santarus report robust revenue growth ahead of merger

  • Salix Pharmaceuticals (SLXP) reports revenue growth of 29% for Q3.
  • Revenue by product: Xifaxan, +20% to $165.9M; Apriso, +93% to $38.1M; Relistor, $4.3M; Moviprep, $19.2M; Solesta, $1.8M; Deflux, $6.6M.
  • Xifaxan prescription growth: 24% Y/Y.
  • FY13 outlook: Revenue of $920M (unchanged). Non-GAAP EPS of $3.20. (PR)
  • Q3 revenues jump 81% Y/Y for Santarus (SNTS), while non-GAAP earnings rise 189%.
  • Revenue by product: Glumetza, $45.6M; Zegerid, $27.1M; Uceris, $19.6M; Cycloset, $4.2M; Fenoglide, $1.6M. (PR)
  • See also: SLXP, SNTS talk synergies, diversification; 2014 guidance provided
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: